Trial Profile
Phase 2 Active Treatment Study to Evaluate the Efficacy and Safety of SRK-015 in Patients With Later-Onset Spinal Muscular Atrophy (TOPAZ)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Apitegromab (Primary)
- Indications Spinal muscular atrophy
- Focus Proof of concept; Therapeutic Use
- Acronyms TOPAZ
- Sponsors Scholar Rock
- 20 Mar 2024 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 19 Mar 2024 According to the Scholar Rock media release, 12-month data from Phase 2 TOPAZ trial presented at American academy of Neurology 2024.
- 07 Nov 2023 According to the Scholar Rock media release, 36 months data from this trial were presented at 28th Annual Congress of the World Muscle Society